Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Registration Number
- NCT04506138
- Lead Sponsor
- Zhejiang Cancer Hospital
- Brief Summary
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
- Histological diagnosis of thoracic Esophageal squamous cell carcinoma
- ECOG performance status 0-1
- Age 18-75 years
- Resectable disease, cT2-4aNanyM0 or cT1-3N+M0
- Life expectancy more than 6 months
- Use of an effective contraceptive for adults to prevent pregnancy
Exclusion Criteria
- Not suitable for surgery
- Prior chemotherapy, radiotherapy and immune-oncology therapies for ESCC
- Prior esophageal, gastric, or gastro-esophageal junction surgery
- Esophageal ulcer, esophageal perforation，chest pain（≥middle level）
- Pregnant or lactating women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Camrelizumab plus Chemotherapy Paclitaxel for Injection (Albumin Bound) - Camrelizumab plus Chemotherapy Camrelizumab - Camrelizumab plus Chemotherapy Carboplatin -
- Primary Outcome Measures
Name Time Method Pathologic complete remission (PCR) 12 weeks Major Pathologic Response (MPR) 12 weeks
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) 5 years Event Free Survival（EFS） 5 years
Trial Locations
- Locations (1)
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China